In the public system, patients with early-stage HER2-positive breast cancer have had access to trastuzumab for only the last 3 years; those with metastatic disease still do not receive any form of targeted anti-HER2 therapy, even though reproducible and consistent benefits have been clearly demonstrated for almost two decades. The gene discussed is ERBB2; the disease is metastatic neoplasm.